Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer
- PMID: 18451232
- PMCID: PMC7295090
- DOI: 10.1158/1078-0432.CCR-07-1760
Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer
Abstract
Purpose: Survivin (BIRC5) is a promising tumor biomarker. Conflicting data exist on its prognostic effect in breast cancer. These data may at least be partly due to the manual interpretation of immunohistochemical staining, especially as survivin can be located in both the nucleus and cytoplasm. Quantitative determination of survivin expression using image analysis offers the opportunity to develop alternative scoring models for survivin immunohistochemistry. Here, we present such a model.
Experimental design: A breast cancer tissue microarray containing 102 tumors was stained with an anti-survivin antibody. Whole-slide scanning was used to capture high-resolution images. These images were analyzed using automated algorithms to quantify the staining.
Results: Increased nuclear, but not cytoplasmic, survivin was associated with a reduced overall survival (OS; P = 0.038) and disease-specific survival (P = 0.0015). A high cytoplasmic-to-nuclear ratio (CNR) of survivin was associated with improved OS (P = 0.005) and disease-specific survival (P = 0.05). Multivariate analysis revealed that the survivin CNR was an independent predictor of OS (hazard ratio, 0.09; 95% confidence interval, 0.01-0.76; P = 0.027). A survivin CNR of >5 correlated positively with estrogen receptor (P = 0.019) and progesterone receptor (P = 0.033) levels, whereas it was negatively associated with Ki-67 expression (P = 0.04), p53 status (P = 0.005), and c-myc amplification (P = 0.016).
Conclusion: Different prognostic information is supplied by nuclear and cytoplasmic survivin in breast cancer. Nuclear survivin is a poor prognostic marker in breast cancer. Moreover, CNR of survivin, as determined by image analysis, is an independent prognostic factor.
Figures



Similar articles
-
Prognostic value of survivin expression in breast cancer patients: a meta-analysis.Tumour Biol. 2013 Aug;34(4):2053-62. doi: 10.1007/s13277-013-0848-2. Epub 2013 May 21. Tumour Biol. 2013. PMID: 23690235 Review.
-
Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer.BMC Cancer. 2010 Nov 23;10:639. doi: 10.1186/1471-2407-10-639. BMC Cancer. 2010. PMID: 21092276 Free PMC article.
-
Survivin subcellular localization in high-grade astrocytomas: simultaneous expression in both nucleus and cytoplasm is negative prognostic marker.J Neurooncol. 2007 Apr;82(2):193-8. doi: 10.1007/s11060-006-9267-1. Epub 2006 Dec 7. J Neurooncol. 2007. PMID: 17151933
-
Nuclear and cytoplasmic cellular distribution of survivin as survival predictor in resected non-small-cell lung cancer.Eur J Surg Oncol. 2008 May;34(5):593-8. doi: 10.1016/j.ejso.2007.06.002. Epub 2007 Aug 10. Eur J Surg Oncol. 2008. PMID: 17693049
-
Nuclear or cytoplasmic expression of survivin: what is the significance?Int J Cancer. 2005 Apr 20;114(4):509-12. doi: 10.1002/ijc.20768. Int J Cancer. 2005. PMID: 15578717 Free PMC article. Review.
Cited by
-
Intratumoral Wnt2B expression affects tumor proliferation and survival in malignant pleural mesothelioma patients.Exp Ther Med. 2012 Jun;3(6):952-958. doi: 10.3892/etm.2012.511. Epub 2012 Mar 12. Exp Ther Med. 2012. PMID: 22969998 Free PMC article.
-
Monitoring survivin expression in cancer: implications for prognosis and therapy.Mol Diagn Ther. 2013 Dec;17(6):331-42. doi: 10.1007/s40291-013-0048-1. Mol Diagn Ther. 2013. PMID: 23912862 Review.
-
Prognostic value of survivin expression in breast cancer patients: a meta-analysis.Tumour Biol. 2013 Aug;34(4):2053-62. doi: 10.1007/s13277-013-0848-2. Epub 2013 May 21. Tumour Biol. 2013. PMID: 23690235 Review.
-
Expression of survivin does not appear to influence breast cancer recurrence risk.Acta Oncol. 2019 Feb;58(2):154-161. doi: 10.1080/0284186X.2018.1503419. Epub 2018 Oct 23. Acta Oncol. 2019. PMID: 30351173 Free PMC article.
-
Improving cancer therapies by targeting the physical and chemical hallmarks of the tumor microenvironment.Cancer Lett. 2016 Sep 28;380(1):330-9. doi: 10.1016/j.canlet.2015.12.019. Epub 2015 Dec 24. Cancer Lett. 2016. PMID: 26724680 Free PMC article. Review.
References
-
- Duffy MJ, O’Donovan N, Brennan DJ, Gallagher WM, Ryan BM. Survivin: a promising tumor biomarker. Cancer Lett 2007;249:49–60. - PubMed
-
- Velculescu VE, Madden SL, Zhang L, et al. Analysis of human transcriptomes. Nat Genet 1999;23:387–8. - PubMed
-
- Ambrosini G, Adida C, Altieri DC. A novel antiapoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917–21. - PubMed
-
- Chu JS, Shew JY, Huang CS. Immunohistochemical analysis of survivin expression in primary breast cancers. J Formos Med Assoc 2004;103:925–31. - PubMed
-
- O’Driscoll L, Linehan R, Kennedy SM, et al. Lack of prognostic significance of survivin, survivin-ΔEx3, survivin-2B, galectin-3, bag-1, bax-α and MRP-1 mRNAs in breast cancer. Cancer Lett 2003;201: 225–36. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous